Your browser doesn't support javascript.
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.
Nomah, Daniel K; Reyes-Urueña, Juliana; Díaz, Yesika; Moreno, Sergio; Aceiton, Jordi; Bruguera, Andreu; Vivanco-Hidalgo, Rosa M; Casabona, Jordi; Domingo, Pere; Navarro, Jordi; Imaz, Arkaitz; Deig, Elisabet; Navarro, Gemma; Llibre, Josep M; Miro, Jose M.
  • Nomah DK; Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona, Spain.
  • Reyes-Urueña J; Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva i de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Díaz Y; Institut d'Investigació Germans Trias i Pujol (IGTP), Barcelona, Spain.
  • Moreno S; Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona, Spain.
  • Aceiton J; Institut d'Investigació Germans Trias i Pujol (IGTP), Barcelona, Spain.
  • Bruguera A; CIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Spain.
  • Vivanco-Hidalgo RM; Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona, Spain.
  • Casabona J; Institut d'Investigació Germans Trias i Pujol (IGTP), Barcelona, Spain.
  • Domingo P; Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona, Spain.
  • Navarro J; Institut d'Investigació Germans Trias i Pujol (IGTP), Barcelona, Spain.
  • Imaz A; Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona, Spain.
  • Deig E; Institut d'Investigació Germans Trias i Pujol (IGTP), Barcelona, Spain.
  • Navarro G; Centre Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Dept Salut, Generalitat de Catalunya, Badalona, Spain.
  • Llibre JM; Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva i de Salut Publica, Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Miro JM; Institut d'Investigació Germans Trias i Pujol (IGTP), Barcelona, Spain.
J Antimicrob Chemother ; 77(8): 2265-2273, 2022 07 28.
Article in English | MEDLINE | ID: covidwho-1890951
ABSTRACT

BACKGROUND:

Reports on the impact of some antiretrovirals against SARS-CoV-2 infection and disease severity are conflicting.

OBJECTIVES:

We evaluated the effect of tenofovir as either tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) against SARS-CoV-2 infection and associated clinical outcomes among people living with HIV (PLWH).

METHODS:

We conducted a propensity score-matched analysis in the prospective PISCIS cohort of PLWH (n = 14 978) in Catalonia, Spain. We used adjusted Cox regression models to assess the association between tenofovir and SARS-CoV-2 outcomes.

RESULTS:

After propensity score-matching, SARS-CoV-2 diagnosis rates were similar in TAF/FTC versus ABC/3TC recipients (11.6% versus 12.5%, P = 0.256); lower among TDF/FTC versus ABC/3TC recipients (9.6% versus 12.8%, P = 0.021); and lower among TDF/FTC versus TAF/FTC recipients (9.6% versus 12.1%, P = 0.012). In well-adjusted logistic regression models, TAF/FTC was no longer associated with reduced SARS-CoV-2 diagnosis [adjusted odds ratio (aOR) 0.90; 95% confidence interval (CI), 0.78-1.04] or hospitalization (aOR 0.93; 95% CI, 0.60-1.43). When compared with ABC/3TC, TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60-1.04) or hospitalization (aOR 0.51; 95% CI, 0.15-1.70). TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60-1.04) or associated hospitalization (aOR 0.33; 95% CI, 0.10-1.07) compared with TAF/FTC.

CONCLUSIONS:

TAF/FTC or TDF/FTC were not associated with reduced SARS-CoV-2 diagnosis rates or associated hospitalizations among PLWH. TDF/FTC users had baseline characteristics intrinsically associated with more benign SARS-CoV-2 infection outcomes. Tenofovir exposure should not modify any preventive or therapeutic SARS-CoV-2 infection management.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: J Antimicrob Chemother Year: 2022 Document Type: Article Affiliation country: Jac

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: J Antimicrob Chemother Year: 2022 Document Type: Article Affiliation country: Jac